19.4 Neurodegenerative Diseases and Cognition

Neurodegenerative Diseases and Their Impact on Cognition

Neurodegenerative diseases progressively destroy neurons in specific brain regions, leading to predictable patterns of cognitive and motor decline. Understanding which brain areas are affected in each disease helps explain why patients show the symptoms they do. This section covers the three major neurodegenerative diseases (Alzheimer's, Parkinson's, and Huntington's), their underlying neuropathology, and how they're diagnosed and treated.

Changes in Neurodegenerative Diseases

Each disease targets different brain structures, which produces a distinct cognitive profile. Knowing these profiles matters for differential diagnosis and for understanding what patients actually experience.

Alzheimer's disease primarily attacks the hippocampus and cerebral cortex, so memory is hit first and hardest.

• Memory loss is the hallmark early symptom. Short-term recall fails first, making it difficult to form new memories. Older memories tend to be preserved longer.
• Executive function decline impairs problem-solving, planning, and managing daily tasks like preparing meals or handling finances.
• Language deterioration shows up as word-finding difficulties (anomia) and reduced comprehension, worsening as the disease progresses.
• Disorientation causes confusion about time, date, and location, even in familiar environments.
• Mood and personality changes include increased irritability, apathy, and social withdrawal.

Parkinson's disease destroys dopamine-producing neurons in the substantia nigra, which is best known for causing tremor and rigidity. But the cognitive effects are significant too.

• Cognitive slowing (bradyphrenia) means delayed information processing and slower responses. This is different from memory loss; the information is still there, but retrieval takes longer.
• Executive function deficits impair organization, planning, and multitasking.
• Visuospatial impairments affect depth perception and spatial navigation, making it hard to judge distances or navigate unfamiliar spaces.
• Attention problems lead to difficulty sustaining focus and increased distractibility.
• Psychiatric symptoms are common. Depression and anxiety frequently co-occur, and some patients develop impulse control disorders (compulsive gambling, shopping, or hypersexuality), sometimes as a side effect of dopamine-related medications.

Huntington's disease is a genetic disorder that degrades the striatum and cortex, producing a combination of motor, cognitive, and psychiatric symptoms.

• Executive dysfunction appears early, impairing decision-making and problem-solving before memory is severely affected.
• Attention and concentration deficits make it hard to stay focused on tasks.
• Memory problems affect both short-term and long-term recall, though the pattern differs from Alzheimer's. Retrieval is more impaired than encoding.
• Emotional disturbances include irritability, depression, and mood swings. Impulsivity and disinhibition can lead to socially inappropriate behaviors.
• Motor symptoms (chorea) cause involuntary, jerky movements that worsen over time and disrupt coordination.

Neuropathology of Disease Progression

These diseases share several common mechanisms of neuronal damage, even though they affect different brain regions and proteins.

General mechanisms across neurodegenerative diseases:

• Protein misfolding and aggregation are central to all three diseases. Misfolded proteins clump together into toxic aggregates that disrupt normal cell function.
• Oxidative stress occurs when free radicals accumulate and damage cellular components, including DNA and cell membranes.
• Mitochondrial dysfunction starves neurons of energy, making them more vulnerable to damage.
• Neuroinflammation involves the brain's immune cells (microglia) mounting a response that can end up damaging healthy tissue alongside diseased tissue.
• Synaptic dysfunction impairs communication between neurons, often beginning before neurons actually die.

Alzheimer's disease pathology involves two signature protein abnormalities:

• Amyloid-beta plaques accumulate in the spaces between neurons, disrupting neural signaling. These extracellular deposits are a key diagnostic marker.
• Neurofibrillary tangles form inside neurons when tau protein becomes hyperphosphorylated and collapses into twisted fibers, blocking intracellular transport.
• Neuronal loss concentrates in the hippocampus (explaining the early memory deficits) and spreads to the cortex as the disease advances.

Parkinson's disease pathology centers on the dopamine system:

• Dopaminergic neurons in the substantia nigra progressively die off, reducing dopamine levels in the basal ganglia. By the time motor symptoms appear, roughly 60-80% of these neurons are already lost.
• Lewy bodies, which are aggregates of alpha-synuclein protein, form within neurons and disrupt cellular function.
• Disruption of basal ganglia circuits impairs both movement control and cognitive processes that depend on dopamine signaling.

Huntington's disease pathology is unique because it has a single, well-defined genetic cause:

• A CAG trinucleotide repeat expansion in the huntingtin gene produces a mutant version of the huntingtin protein. The longer the repeat, the earlier the disease tends to onset.
• Mutant huntingtin aggregates form toxic clumps inside neurons.
• Striatal and cortical atrophy progresses over time, producing the characteristic combination of motor, cognitive, and psychiatric decline.

Diagnosis and Treatment of Neurodegenerative Diseases

Assessment of Neurodegenerative Disorders

Diagnosing neurodegenerative diseases requires multiple lines of evidence because no single test is definitive (especially in early stages). Clinicians combine clinical evaluation, imaging, and biomarkers to build a complete picture.

Clinical assessment is always the starting point:

• Medical history gathers information about symptom onset, rate of progression, family history, and risk factors.
• Physical and neurological examination evaluates motor function, reflexes, gait, and sensory responses.
• Cognitive testing uses standardized tools like the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) to measure performance across cognitive domains (memory, attention, language, visuospatial ability).
• Behavioral and psychiatric evaluation identifies co-occurring mood disorders, personality changes, or psychotic symptoms.

Neuroimaging techniques allow clinicians to visualize brain changes:

• MRI reveals brain structure and can detect patterns of atrophy (e.g., hippocampal shrinkage in Alzheimer's).
• PET scans measure metabolic activity and can detect specific protein aggregates like amyloid and tau deposits.
• SPECT assesses cerebral blood flow and dopamine transporter levels, which is particularly useful for Parkinson's diagnosis.

Biomarkers provide molecular evidence of disease:

• Cerebrospinal fluid (CSF) analysis measures levels of disease-specific proteins. In Alzheimer's, low amyloid-beta and high tau in CSF are characteristic.
• Blood-based biomarkers are a newer and less invasive option. Neurofilament light chain (NfL) is a general marker of neurodegeneration detectable in blood.
• Genetic testing can identify disease-causing mutations (like the huntingtin gene CAG expansion) or risk factors (like the APOE ε4 allele, which increases Alzheimer's risk).

Diagnostic criteria provide standardized frameworks. The DSM-5 classifies these conditions under major and mild neurocognitive disorders, and disease-specific criteria (such as the NIA-AA criteria for Alzheimer's) help ensure accurate and consistent diagnosis.

Treatment Options for Cognitive Functioning

There is currently no cure for any of these diseases. Treatment focuses on managing symptoms, maintaining function as long as possible, and improving quality of life.

Current pharmacological treatments:

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are used in Alzheimer's. They boost acetylcholine levels in the brain, modestly improving cognitive symptoms. They don't stop the disease from progressing.
• Levodopa and dopamine agonists are the mainstay for Parkinson's. They replenish dopamine signaling, primarily alleviating motor symptoms but sometimes improving cognitive function as well.
• Tetrabenazine reduces chorea (involuntary movements) in Huntington's by depleting dopamine in the basal ganglia.

Non-pharmacological interventions play an important complementary role:

• Cognitive stimulation therapy engages patients in structured mentally stimulating activities to help maintain cognitive function.
• Physical exercise improves cardiovascular health and has shown evidence of slowing cognitive decline across multiple diseases.
• Occupational therapy helps patients adapt to cognitive changes and maintain independence in daily activities.
• Speech and language therapy addresses communication difficulties and, in later stages, swallowing problems.

Emerging therapies represent active areas of research:

• Immunotherapies target protein aggregates, aiming to clear toxic amyloid or tau from the brain. Lecanemab, an anti-amyloid antibody, received FDA approval for early Alzheimer's in 2023, though its clinical benefit remains modest.
• Gene therapies attempt to correct or compensate for disease-causing mutations, with Huntington's disease being a prime target given its single-gene cause.
• Stem cell treatments explore the potential for replacing lost neurons, though this remains largely experimental.
• Neuroprotective agents aim to slow or halt neurodegeneration rather than just treating symptoms.

Potential future approaches:

• Personalized medicine would tailor treatments based on a patient's genetic profile and specific disease biomarkers.
• Combination therapies targeting multiple pathological pathways simultaneously may prove more effective than single-target drugs.
• Brain-computer interfaces could potentially compensate for lost cognitive or motor functions.
• Nanotechnology-based drug delivery could improve the ability to get treatments across the blood-brain barrier and to specific brain regions.